Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Contenu indisponible. Consultez la source originale.
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.